NasdaqGM - Nasdaq Real Time Price USD

Avidity Biosciences, Inc. (RNA)

24.09 -1.00 (-3.98%)
As of 2:49 PM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Troy Edward Wilson J.D., Ph.D. Co-Founder & Chairman 67.5k -- 1969
Ms. Sarah Boyce President, CEO & Director 1.05M 1.08M 1972
Mr. Michael F. MacLean Chief Financial & Chief Business Officer 701.64k -- 1966
Dr. W. Michael Flanagan Ph.D. Chief Scientific & Technical Officer 678.74k -- 1962
Ms. Teresa McCarthy Chief Human Resources Officer 665.14k -- 1964
Mr. Eric B. Mosbrooker Chief Strategy Officer 42.5k -- 1968
Prof. Mark E. Davis Scientific Founder, Member of Scientific Advisory Board and Member of Board of Managers -- -- --
Dr. Frank P. McCormick Ph.D. Scientific Founder & Member of Scientific Advisory Board -- -- 1950
Mr. Geoffrey M. Grande C.F.A. VP of Investor Relation & Corporate Communication -- -- --
Dr. John W. Wallen III VP of Intellectual Property, General Counsel & Secretary -- -- 1958

Avidity Biosciences, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
United States
858 401 7900 https://www.aviditybiosciences.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
253

Description

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Corporate Governance

Avidity Biosciences, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 07, 2024 - May 13, 2024
Avidity Biosciences, Inc. Earnings Call

Related Tickers

DYN Dyne Therapeutics, Inc.
23.70
-5.12%
 
SANA Sana Biotechnology, Inc.
8.43
-1.81%
 
SYRE Spyre Therapeutics, Inc.
32.77
-0.67%
 
RVMD Revolution Medicines, Inc.
35.41
-0.52%
 
VERA Vera Therapeutics, Inc.
38.05
-4.76%
 
KURA Kura Oncology, Inc.
19.04
+1.55%
 
FDMT 4D Molecular Therapeutics, Inc.
23.75
-2.08%
 
JANX Janux Therapeutics, Inc.
46.96
-2.60%
 
AKRO Akero Therapeutics, Inc.
19.02
-6.12%
 
NRIX Nurix Therapeutics, Inc.
12.66
-7.93%